Processa Pharmaceuticals, Inc. Deferred Tax Liabilities, Tax Deferred Income
Processa Pharmaceuticals, Inc. (PCSA) had Deferred Tax Liabilities, Tax Deferred Income of $1.78 thousand as of 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome · last filed 2021-03-25
- 2019-09-30: Deferred Tax Liabilities, Tax Deferred Income $1.78K.
- 2019-06-30: Deferred Tax Liabilities, Tax Deferred Income $1.78K.
- 2019-03-31: Deferred Tax Liabilities, Tax Deferred Income $1.78K.
- 2018-12-31: Deferred Tax Liabilities, Tax Deferred Income $1.78K.
| Period end | Deferred Tax Liabilities, Tax Deferred Income |
|---|---|
| 2019-09-30 | $1.78K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $1.78K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $1.78K 10-Q · filed 2019-05-14 |
| 2018-12-31 | $1.78K 10-K/A · filed 2019-04-08 |
| 2018-09-30 | $1.78K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $1.78K 10-Q · filed 2018-08-14 |
| 2018-03-31 | $1.78K 10-Q · filed 2018-05-21 |
| 2018-03-19 | $1.78K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |